PCPI® is a membership organization uniquely focused on improving health outcomes through the advancement of performance measurement, clinical registries and quality improvement initiatives. Since 2000, PCPI has been a leader in convening experts to develop performance measures that improve the quality of healthcare for stakeholders across all of healthcare. We have a proven commitment to quality and have developed over 300 performance measures, 90 endorsed by NQF.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

BIOTECH STARTUP MEKONOS RAISES OVERSUBSCRIBED $25 MILLION ROUND TO OVERCOME PHARMA INDUSTRY'S CELL & GENE THERAPY DELIVERY HURDLES

Mekonos, Inc. | November 10, 2021

news image

Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, including Novartis Pharma AG (dRx Capital) and Elementum Ventures, also joined in the funding round that will...

Read More

INTENT DATA IN THE AGE OF DATA REGULATION

DECK 7 | March 23, 2020

news image

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while rem...

Read More

INDUSTRIAL IMPACT

HESKA TO ACQUIRE LIGHTDECK DIAGNOSTICS TO INVEST IN MANUFACTURING CAPABILITIES AND ACCELERATE RESEARCH AND DEVELOPMENT EFFORTS

LightDeck Diagnostics and Heska | September 13, 2022

news image

Heska Corporation a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics a pioneer in innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities. Founded in 2009 and headquartered in Boulder, Colorado, LightDeck has develope...

Read More

INDUSTRIAL IMPACT

SECOND GENOME ANNOUNCES BAYER EXERCISED OPTION FOLLOWING COMPLETION OF MULTI-YEAR COLLABORATION

Second Genome | March 03, 2022

news image

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced today it has completed its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products. During the collaboration, Second Genome generated and explored environmental metagenomes that include genomic information from bacteria that are yet to be identified and cultured. Read More

news image

CELL AND GENE THERAPY

BIOTECH STARTUP MEKONOS RAISES OVERSUBSCRIBED $25 MILLION ROUND TO OVERCOME PHARMA INDUSTRY'S CELL & GENE THERAPY DELIVERY HURDLES

Mekonos, Inc. | November 10, 2021

Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, including Novartis Pharma AG (dRx Capital) and Elementum Ventures, also joined in the funding round that will...

Read More
news image

INTENT DATA IN THE AGE OF DATA REGULATION

DECK 7 | March 23, 2020

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while rem...

Read More
news image

INDUSTRIAL IMPACT

HESKA TO ACQUIRE LIGHTDECK DIAGNOSTICS TO INVEST IN MANUFACTURING CAPABILITIES AND ACCELERATE RESEARCH AND DEVELOPMENT EFFORTS

LightDeck Diagnostics and Heska | September 13, 2022

Heska Corporation a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics a pioneer in innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities. Founded in 2009 and headquartered in Boulder, Colorado, LightDeck has develope...

Read More
news image

INDUSTRIAL IMPACT

SECOND GENOME ANNOUNCES BAYER EXERCISED OPTION FOLLOWING COMPLETION OF MULTI-YEAR COLLABORATION

Second Genome | March 03, 2022

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced today it has completed its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products. During the collaboration, Second Genome generated and explored environmental metagenomes that include genomic information from bacteria that are yet to be identified and cultured. Read More